Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Quantum Genomics (QGC) has initiated the Phase I study of QGC001 drug candidate in healthy volunteers following the approval from the French Agency for Safety of Health Products (AFSSAPS).
Subscribe to our email newsletter
QGC001 is the first of a new class of drugs that can to monitor high blood pressure by inhibiting the aminopeptidase A enzyme (APA) at the brain level.
The First-in-Human clinical trial is a single ascending oral dose double-blind and placebo-controlled Phase I study proposed to evaluate the overall safety, tolerability and pharmacokinetics of QGC001 for treating hypertensive patients particularly those with Low Renin High Vasopressin profile (LRHV).
Quantum Genomics CEO Lionel Segard said the first study in human demonstrates the company’s ability to develop an innovative compound originated from academic research.
"QGC001 is the first representative of a new class of antihypertensive drugs that may improve the control of blood pressure in many patients with no current appropriate drug treatment and reduce their concomitant risks of cardiovascular diseases," Segard added.